Publikationen, an denen er mitarbeitet Norma C. Gutiérrez (21)

2024

  1. PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

    Leukemia

  2. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  3. Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling

    Haematologica, Vol. 109, Núm. 3, pp. 877-887

  4. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2022

  1. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research

  2. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

  3. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group

    Blood cancer journal, Vol. 12, Núm. 4, pp. 76

2021

  1. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

2020

  1. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  2. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

  3. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

    Blood Cancer Journal, Vol. 10, Núm. 2

2017

  1. Differentiation stage of myeloma plasma cells: Biological and clinical significance

    Leukemia, Vol. 31, Núm. 2, pp. 382-392

2016

  1. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis

    Blood, Vol. 127, Núm. 24, pp. 3035-3039

2015

  1. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers

    Genome Research, Vol. 25, Núm. 4, pp. 478-487

2008

  1. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia

    British Journal of Haematology, Vol. 142, Núm. 4, pp. 571-582

  2. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression

    Haematologica, Vol. 93, Núm. 4, pp. 560-565

2006

  1. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study

    Blood, Vol. 108, Núm. 7, pp. 2165-2172

  2. Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain

    Leukemia Research, Vol. 30, Núm. 8, pp. 943-948

2004

  1. Heterogeneity of structural abnormalities in the 7q31.3∼q34 region in myeloid malignancies

    Cancer Genetics and Cytogenetics

2003

  1. Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study

    Leukemia, Vol. 17, Núm. 10, pp. 2016-2024